Metronomic Cyclophosphamide With Cisplatin and Bevacizumab for Refractory Anaplastic Ependymoma: A Retrospective Study.
Fiche publication
Date publication
août 2022
Journal
Anticancer research
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François
Tous les auteurs :
DE Laclos XC, Frappaz D, Ahle G, Bronnimann C, Catry-Thomas I, Joncour A, Ghiringhelli F, Vauleon E
Lien Pubmed
Résumé
Anaplastic ependymoma is a rare cancer of the central nervous system. The treatment includes optimal resection with focal radiotherapy. Some case reports or retrospective studies have suggested efficacy of regimens containing platinum or bevacizumab. We describe the feasibility and clinical benefit of the cisplatin-bevacizumab-cyclophosphamide treatment of anaplastic ependymoma.
Mots clés
Chemotherapy, anaplastic ependymoma, refractory
Référence
Anticancer Res. 2022 08;42(8):3863-3867